DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia

by Michael I. Carr, Astrid Zimmermann, Li-Ya Chiu, Frank T. Zenke, Andree Blaukat, Lyubomir T. Vassilev
Published 2020-02-01

Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality

by Salvatore Benfatto, Özdemirhan Serçin, Francesca R. Dejure, Amir Abdollahi, Frank T. Zenke, Balca R. Mardin
Published 2021-08-01

A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice

by Paris Roidos, Stephanie Sungalee, Salvatore Benfatto, Özdemirhan Serçin, Adrian M. Stütz, Amir Abdollahi, Jan Mauer, Frank T. Zenke, Jan O. Korbel, Balca R. Mardin
Published 2020-08-01

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

by Eric Haines, Yuki Nishida, Michael I. Carr, Rafael Heinz Montoya, Lauren B. Ostermann, Weiguo Zhang, Frank T. Zenke, Andree Blaukat, Michael Andreeff, Lyubomir T. Vassilev
Published 2021-06-01

A solid‐phase transfection platform for arrayed CRISPR screens

by Özdemirhan Serçin, Sabine Reither, Paris Roidos, Nadja Ballin, Spyridon Palikyras, Anna Baginska, Katrin Rein, Maria Llamazares, Aliaksandr Halavatyi, Hauke Winter, Thomas Muley, Renata Z Jurkowska, Amir Abdollahi, Frank T Zenke, Beate Neumann, Balca R Mardin
Published 2020-06-01

A solid‐phase transfection platform for arrayed CRISPR screens

by Özdemirhan Serçin, Sabine Reither, Paris Roidos, Nadja Ballin, Spyridon Palikyras, Anna Baginska, Katrin Rein, Maria Llamazares, Aliaksandr Halavatyi, Hauke Winter, Thomas Muley, Renata Z Jurkowska, Amir Abdollahi, Frank T Zenke, Beate Neumann, Balca R Mardin
Published 2019-12-01